Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology-Clinical Diagnosis: Neuroendocrine

A comparison of 68Gallium-DOTA-TOC and 18F-FDG PET/CT in imaging of neuroendocrine tumors (NETs)

Niraj Naswa, C. Bal, Snehlata Lata, Ramamohan Reddy and Arun Malhotra
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 405;
Niraj Naswa
1Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Bal
1Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Snehlata Lata
1Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramamohan Reddy
1Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arun Malhotra
1Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

405

Objectives Our purpose was to compare the performance of 68Ga-1,4,7, 10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-D-Phe1,Tyr3-octreotide (DOTA-TOC), a novel selective somatostatin receptor 2 PET ligand, and 18F-FDG in the detection of NETs using PET/CT with emphasis on the following aspects-staging, restaging, monitoring response to therapy, prediction of prognosis, selection of appropriate therapy and establish a possible relationship between SSTR and glucose metabolic status.

Methods Ninety patients (50men,40women;mean age 42.5 yrs) underwent the above two imaging studies. Study population was divided into two groups. The first group comprised of patients (n=48) who were already treated and had histopathological confirmation of their diagnosis, while the other group (n=42) was referred for detection of unknown primary NET (CUP-NET).

Results Results of 18F-FDG were reported as positive in 41 patients. Mean SUVmax of the lesions were 3.42. 68Ga-DOTA-TOC PET/CT was reported as positive in 76 cases with a mean SUvmax of 9.0, an overall higher lesion detection rate and sensitivity compared to 18F-FDG PET/CT (95% Vs 53%).

Conclusions Although 68Ga-DOTA-TOC PET/CT performed better than 18F-FDG PET/CT, the implication of both studies are different. 68Ga-DOTATOC PET/CT was superior in localizing the primary tumor and for restaging purpose while 18F-FDG PET/CT revealed information which were more important from therapeutic point of view and determination of prognosis ( a higher FDG uptake portends a poor prognosis).Further there is a possible inverse relationship between SSTR and glucose metabolic status(SSTR expression is a feature of well-differentiated tumor while FDG uptake is a marker of anaplasia)

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 51, Issue supplement 2
May 2010
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A comparison of 68Gallium-DOTA-TOC and 18F-FDG PET/CT in imaging of neuroendocrine tumors (NETs)
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
A comparison of 68Gallium-DOTA-TOC and 18F-FDG PET/CT in imaging of neuroendocrine tumors (NETs)
Niraj Naswa, C. Bal, Snehlata Lata, Ramamohan Reddy, Arun Malhotra
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 405;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A comparison of 68Gallium-DOTA-TOC and 18F-FDG PET/CT in imaging of neuroendocrine tumors (NETs)
Niraj Naswa, C. Bal, Snehlata Lata, Ramamohan Reddy, Arun Malhotra
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 405;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology-Clinical Diagnosis: Neuroendocrine

  • Comparison of 18F-FDG PET and 99mTc-TOC scintigraphy in patients with neuroendocrine tumor
  • Glucagon-like peptide-1 vs. somatostatin receptor targeting in malignant insulinoma
  • Detection of intestinal NET by (68)Ga-DOTATOC PET/multiphase CT
Show more Oncology-Clinical Diagnosis: Neuroendocrine

Neuroendocrine Cancers

  • Comparison of 18F-FDG PET and 99mTc-TOC scintigraphy in patients with neuroendocrine tumor
  • Glucagon-like peptide-1 vs. somatostatin receptor targeting in malignant insulinoma
  • Detection of intestinal NET by (68)Ga-DOTATOC PET/multiphase CT
Show more Neuroendocrine Cancers

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire